Dr Philip McMillan

Physician and researcher with an innovative approach to COVID-19 and international keynote speaker. First to outline a theory of autoimmunity in COVID-19 in April 2020. Sharing valuable research on science and health through LinkedIn Live interviews and regular posts.

Since the start of the COVID-19 pandemic, I have applied my research technique, which has been successful in dementia, to help understand COVID-19. I have observed that the primary pathology of the disease is typically several steps away from visible symptoms. In the case of COVID-19, I have proposed that severe disease is a viral-mediated autoimmune response. In April 2020, I first outlined the theory of autoimmunity in COVID-19 based on the interaction between the viral spike protein and serum ACE-2, which was subsequently published in a paper co-authored by Prof Bruce Uhal, the top pulmonary ACE-2 researcher worldwide. Research at Johns Hopkins University has since (October 2020) confirmed autoantibodies to ACE-2 in the serum of severely affected patients, supporting the theory of autoimmunity in COVID-19. I am working towards carrying this research forward with the support of a team of international experts.